Viability and Safety of Combination Drug Therapies for Erectile Dysfunction
- 1 August 2003
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 170 (2), S20-S23
- https://doi.org/10.1097/01.ju.0000075120.89700.9b
Abstract
In some patients with erectile dysfunction (ED) oral, topical or intracavernous drug therapy fails. However, several classes of drugs demonstrate efficacy for ED, creating the potential for pharmacological combinations preferable to implantation of a penile prosthesis. Preliminary reports suggest that combining oral, topical or intracavernous drugs may salvage patients in whom monotherapy fails. Agents that lead to activation or increases in cyclic nucleotides (cyclic adenosine monophosphate and guanosine monophosphate) with or without nitric oxide donors or nitrates, or alpha-adrenergic antagonists have been used to treat ED. The phosphodiesterase-5 inhibitor sildenafil has been combined with alprostadil (prostaglandin E1) and administered by either the intraurethral or intracavernous route. Successful intercourse following this combination varies from 47% to 100% when monotherapy with each has failed. The introduction of apomorphine has led to its unapproved use in combination with sildenafil in Europe. Combination strategies may allow lower drug doses and reduced adverse effects. The encouraging preliminary observations combined with the potential for adverse events provide a scientific rationale for prospective, randomized clinical trials with adequate numbers of subjects.Keywords
This publication has 16 references indexed in Scilit:
- Nitric Oxide Independent Activation of Guanylate Cyclase by YC-1 Causes Erectile Responses in the RatJournal of Urology, 2002
- Combined oral therapy with sildenafil and doxazosin for the treament of non-organic erectile dysfunction refractory to sildenafil monotherapyInternational Journal Of Impotence Research, 2002
- Rationale for combination therapy of intraurethral prostaglandin E1 and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapyInternational Journal Of Impotence Research, 2002
- Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunctionInternational Journal Of Impotence Research, 2002
- Current status of local penile therapyInternational Journal Of Impotence Research, 2002
- DIRECT EFFECTS OF SELECTIVE TYPE 5 PHOSPHODIESTERASE INHIBITORS ALONE OR WITH OTHER VASODILATORS ON THE ERECTILE RESPONSE IN CATSJournal of Urology, 2001
- SILDENAFIL VERSUS INTRACAVERNOUS INJECTION THERAPY: EFFICACY AND PREFERENCE IN PATIENTS ON INTRACAVERNOUS INJECTION FOR MORE THAN 1 YEARJournal of Urology, 2000
- SWITCHING FROM INTRACAVERNOUS PROSTAGLANDIN E1 INJECTIONS TO ORAL SILDENAFIL CITRATE IN PATIENTS WITH ERECTILE DYSFUNCTION: RESULTS OF A MULTICENTER EUROPEAN STUDYJournal of Urology, 2000
- POTENTIATION OF ERECTILE RESPONSE AND cAMP ACCUMULATION BY COMBINATION OF PROSTAGLANDIN E1AND ROLIPRAM, A SELECTIVE INHIBITOR OF THE TYPE 4 PHOSPHODIESTERASE (PDE 4)Journal of Urology, 1999
- THE EFFECT OF SILDENAFIL ON APOMORPHINE-EVOKED INCREASES IN INTRACAVERNOUS PRESSURE IN THE AWAKE RATJournal of Urology, 1999